Loading
A phase 2 trial of Paclitaxel / nab-paclitaxel, Pertuzumab, Margetuximab, Trastuzumab and Trastuzumab biosimilars in Breast cancer and HER2-positive breast cancer, run by Dana-Farber Cancer Institute, active and no longer recruiting.
MARGetuximab Or Trastuzumab (MARGOT) is a phase 2 interventional study registered as NCT04425018 by Dana-Farber Cancer Institute, with 174 participants planned, started 2020-07-13 and due to reach its primary completion in 2024-10-24. Interventions recorded: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab. Conditions recorded: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer.
Linked to the drug Margetuximab because the registry names it among its interventions and Breast cancer and HER2-positive breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Trastuzumab biosimilars, Trastuzumab, Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Margetuximab, Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares Trastuzumab biosimilars, Pertuzumab, Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares Early HER2-positive breast cancer, Pertuzumab, HER2-positive breast cancer and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
Shares Early HER2-positive breast cancer, Pertuzumab, HER2-positive breast cancer and the tag pipeline.
Shares Margetuximab, Trastuzumab and the tag pipeline.